|Mr. Habib J. Dable||Chief Exec. Officer, Pres and Director||472.76k||N/A||48|
|Dr. Thomas P. Maniatis Ph.D.||Co-Founder, Chairman of Scientific Advisory Board and Director||40k||N/A||74|
|Mr. Kevin F. McLaughlin||Chief Financial Officer, Sr. VP and Treasurer||522.36k||608.21k||61|
|Dr. Ravindra Kumar Ph.D.||Chief Scientific Officer and Sr. VP||486.25k||1.37M||57|
|Dr. Matthew L. Sherman M.D.||Chief Medical Officer and Exec. VP||605.43k||1.38M||61|
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companys therapeutic candidates also include Dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Acceleron Pharma Inc.’s ISS Governance QualityScore as of May 1, 2017 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 7.